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Arezzo and Siena, ItalyObjectives This study sought to compare paclitaxel-eluting balloon (PEB) with conventional
percutaneous transluminal angioplasty (PTA), followed by systematic implantation of a self-expanding
nitinol bare-metal stent (BMS) in patients at risk for restenosis.
Background PTA is an effective strategy for treating atherosclerosis of the femoropopliteal axis (FPA).
Whereas PEB have shown advantage over uncoated balloons in the treatment of simple lesions, it is
unknown whether these results are applicable to complex degrees of FPA atheroma.
Methods A total of 104 patients (110 FPA lesions in 110 limbs) were randomly assigned to either
PEB þ BMS or PTA þ BMS. The primary endpoint was 12-month binary restenosis. Secondary
endpoints were freedom from target lesion revascularization and major amputation. Post hoc
subanalyses were performed for the comparison of long (100 mm) versus short lesions and true
lumen versus subintimal approach.
Results Mean lesion length was 94  60 versus 96  69 mm in the PEB þ BMS and PTA þ BMS
groups (p ¼ 0.8), respectively. The primary endpoint occurred in 9 (17%) versus 26 (47.3%) of lesions in
the PEB þ BMS and PTA þ BMS groups (p ¼ 0.008), respectively. A near-signiﬁcant (p ¼ 0.07) 1-year
freedom from target lesion revascularization advantage was observed in the PEB þ BMS group. No
major amputation occurred. No signiﬁcant difference was observed according to lesion characteristics
or technical approach.
Conclusions Pre-dilation with PEB angioplasty prior to BMS implantation, as compared to PTA þ BMS
in complex FPA lesions, reduces restenosis and target lesion revascularization at 12-month follow-up.
Restenosis reduction is maintained irrespective of lesion length and recanalization technique.
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1296Endovascular intervention is considered the treatment of
choice for peripheral artery disease of variable severity (1). In
particular, percutaneous transluminal angioplasty (PTA),
frequently followed by stent implantation (2), is used for
treating, with high initial success rate, the challenging
atherosclerosis of the femoropopliteal axis (FPA), often
characterized by long, calciﬁc total occlusions (2–5). The
main drawback of this strategy, however, is its unacceptable
restenosis rate, ranging from 40% to 60% at 12 months (6).
Different from the coronary vasculature, limus-based drug-
eluting stents (DES) have failed to demonstrate sustained
effectiveness in the FPA setting (7–9), whereas encouraging
results have been reported for a paclitaxel-eluting polymer-
free nitinol self-expanding DES (10). These ﬁndings have
raised the question of whether the drug itself, the polymer
coating, or the stent platform is the key to long-term successAbbreviations
and Acronyms
BMS = bare-metal stent(s)
CLI = critical limb ischemia
DAPT = dual antiplatelet
therapy
DEB = drug-eluting balloon(s)
DES = drug-eluting stent(s)
DUS = duplex
ultrasonography
FPA = femoropopliteal axis
ISR = in-stent restenosis





TLR = target lesionin the FPA.
Drug-eluting balloons (DEB),
a treatment modality that allows
homogeneous delivery of an an-
tiproliferative drug (paclitaxel-
eluting balloon [PEB]) to the
vessel wall without leaving pros-
thetic material behind, are an
effective strategy for treating
FPA lesions (11–14). However, it
is unknown whether these results
might be applicable to relatively
complex degrees of FPA athero-
sclerosis, which may require
mechanical scaffolding to avoid
elastic recoil and prevent occlu-
sive dissections (15). Therefore,
in this setting, the combination of
DEB with stenting might be an
important concept to explore as
a treatment modality.The aim of the DEBATE-SFA (Drug Eluting Balloon in
Peripheral Intervention for the Superﬁcial Femoral Artery)
trial was to investigate the safety and efﬁcacy of PEB
angioplasty compared with pre-dilation with conventional
uncoated balloon catheters before systematic implantation of
a self-expanding nitinol stent in terms of reduction of
restenosis in a population with FPA artery stenosis or
occlusion.
Methods
Study design. The DEBATE-SFA trial was a prospective,
single-center, randomized, parallel-group, open-label
involving the blinded evaluation of endpoints trial (16). It
was approved by the local ethics committee and was carried
out in accordance with the Helsinki declaration. All patients
provided written informed consent.
revascularization(s)Patients. We prospectively enrolled 104 patients with 110
lesions in 110 limbs presenting with either intermittent
claudication or critical limb ischemia (CLI), selected from
177 patients consecutively referred to the catheterization
laboratory of our institution for peripheral angiography
and percutaneous revascularization between November 2010
and November 2011. Eligible patients were older than 18
years. Angiographic inclusion criteria were: de novo stenosis
50% or occlusion of at least 40 mm in length located in the
superﬁcial femoral artery or popliteal artery; presence of
a clear healthy segment between the lesion in the superﬁcial
femoral artery and common femoral artery and between
the popliteal and tibioperoneal trunk; and presence of at least
1 patent tibial vessel with distal runoff (below-the-knee
artery was considered patent if free from obstructive lesions
determining angiographic stenosis >70%). Exclusion criteria
were: life expectancy <1 year; contraindication for com-
bined antiplatelet therapy; known allergy to nickel or
paclitaxel; and need for major amputation at the time of
enrollment. Failure to recanalize intended below-the-knee
arteries in CLI patients at risk of major amputation was
also considered an exclusion criterion. After enrollment
and before angioplasty, lesions were randomly assigned 1:1
to undergo either PEB followed by nitinol bare-metal
stent (BMS) implantation (PEB þ BMS group) or standard
PTA followed by nitinol stent implantation (PTA þ BMS
group) according to a computer-generated random series
of numbers. Randomization was performed by block ran-
domization (blocks of 10 patients).
In patients requiring bilateral FPA revascularization, the
second limb was treated within 1 month from the ﬁrst
intervention.
Procedures. Angiography, angioplasty, and stent implanta-
tion were performed according to institutional standards.
Vascular access was obtained through the common femoral
artery, in either antegrade or retrograde fashion, according to
anatomical characteristics and lesion location, using a 6-F
sheath to achieve adequate support. All patients were
administered an intra-arterial bolus of unfractionated
heparin (70 to 100 U/kg). After diagnostic angiography,
a conventional guidewire was advanced to cross the target
lesion. Multilevel, multivessel, and bilateral interventions
were allowed as clinically needed. Long diffuse lesions or
multiple adjacent lesions were cumulatively considered and
treated as a single target.
All lesions underwent pre-dilation with an uncoated
balloon, undersized with respect to the vessel diameter.
Thereafter, in patients randomized to PTA þ BMS, a
nitinol stent was implanted, whereas in the PEB þ BMS
group, further dilation of at least 120 s with a paclitaxel-
coated balloon (In.Pact Admiral, Invatec/Medtronic, Santa
Rosa, California), maintaining a vessel/balloon diameter
ratio of 1:1 preceded nitinol stent implantation. Size and
length of PEB were chosen, referring to a ruler placed
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1297behind the patient’s leg; sizing was 1:1 to the reference
vessel diameter. All stents in both groups were post-dilated
with conventional balloon, maintaining a vessel/balloon
diameter ratio of 1:1.
The In.Pact system features the balloon with FreePac,
a proprietary, natural coating. The hydrophilic spacer,
necessary to separate paclitaxel molecules and facilitate
drug elution into the arterial wall, is urea. This technology
is able to release the majority of the drug within the ﬁrst
30 s. The paclitaxel concentration is 3 mg/mm2 and the
total drug load depends on both size and length of the
balloon (17).
PEB was inﬂated from 10 mm proximal to 10 mm distal
to the target lesion; in lesions requiring >1 balloon, a 5-mm
balloon overlap was allowed to obtain a uniform drug elu-
tion in the treated vessel. Self-expanding nitinol stents
(Maris, Invatec/Medtronic) were then implanted in all
lesions. The stent dimensions were chosen such that the
nominal diameter exceeded the reference vessel diameter
by 1 mm and the length exceeded the lesion length by about
5 mm proximal and distal in order to stay within the pre-
dilation area. Deployment of a second stent was allowed in
cases where 1 stent did not cover the entire lesion, was
positioned incorrectly, or a dissection extended beyond the
stent margins. In this case, further pre-dilation with DEB
was always performed to ensure complete drug coverage of
the stented segment. Technical success was deﬁned asFigure 1. Study Flow
BMS ¼ bare-metal stent(s); BTK ¼ below-the-knee lesion; DAPT ¼ dual antiplatelet th
balloon; PTA ¼ percutaneous transluminal angioplasty; TLR ¼ target lesion revascularesidual stenosis <30% by visual estimation. Procedural
success was deﬁned as achievement of technical success
without complications. Femoral sheaths were removed when
activated clotting time was <150 s, achieving access site
hemostasis by manual compression in all patients. All
patients received dual antiplatelet therapy ([DAPT] aspirin
100 mg/day plus clopidogrel 75 mg/day). Patients not
already taking clopidogrel or aspirin were administered
a loading dose of 300 mg of each drug at least 12 h before
the procedure. Aspirin was then continued indeﬁnitely,
whereas clopidogrel was continued for 1 month and
3 months, respectively, in PTA þ BMS and PEB þ BMS
groups.
Follow-up. Post-operative evaluation was deferred to
physicians who were unaware of the assigned intervention.
At 12 months, target lesions were evaluated by repeat
angiography; in the case of consent withdrawal for angiog-
raphy or presence of severe renal impairment, a duplex
ultrasonography (DUS) scan was performed. All target
lesion revascularizations (TLR) were clinically driven and
conﬁrmed angiographically before treatment.
Endpoints and deﬁnitions. The outcome was documented
with angiography. Before, immediately after the interven-
tion, and 12 months later, angiography of the target vessel
was performed in identical projections (2 orthogonal planes
for each treated lesion). The target lesion was identiﬁed by
an image of the vascular anatomy and speciﬁc landmarkserapy; DUS ¼ duplex ultrasonography; FUP ¼ follow-up; PEB ¼ paclitaxel-eluting
rization.




(n ¼ 51) p Value
Age, yrs 74  9 76  8 0.2
Female 13 (24.5) 19 (37.3) 0.3
Diabetes 41( 77.4) 36 (70.6) 0.5
Hypertension* 47 (88.7) 45 (88.2) 1
Dyslipidemiay 33 (62.3) 27 (52.9) 0.4
Smokers 25 (47.2) 28 (54.9) 0.4
Coronary artery disease 21 (39.6) 18 (35.3) 0.7
Cerebrovascular disease 11 (20.8) 9 (17.6) 0.8
Dialysis 5 (9.4) 3 (5.9) 0.7
Intermittent claudication 11 (20.8) 16 (31.4) 0.2
Critical limb ischemia 42 (79.2) 35 (68.6) 0.2
ABI 0.33  0.22 0.31  0.18 0.6
Rutherford class, %
3 11 (20.8) 16 (31.4) 0.5
4 11 (20.8) 11 (21.6)
5 29 (54.7) 21 (41.1)
6 2 (3.7) 3 (5.9)
Values are mean  SD or % (n). *Hypertension was deﬁned as serial blood pressure
measurements >140/90 mm Hg. yDyslipidemia was deﬁned as history of increased low-density
lipoprotein, triglycerides, and/or low high-density lipoprotein or use of lipid-lowering agents.
ABI ¼ ankle-brachial index; BMS ¼ bare-metal stent; PEB ¼ paclitaxel-eluting balloon;
PTA ¼ percutaneous transluminal angioplasty.




(n ¼ 55) p Value
SFA location 41 (74.5) 45 (81.8) 0.5
Popliteal location 14 (25.5) 10 (18.2) 0.5
Lesion length, mm 94  60 96  69 0.8
Total occlusions 30 (54.5) 38 (69.1) 0.1
RVD baseline, mm 5.01  0.5 5.12  0.5 0.5
MLD baseline, mm* 0 (0/1) 0 (0/0.78) 0.06
DS baseline, % 91  10 94  9 0.1
MLD post stent, mm 4.87  0.56 4.89  0.49 0.9
Calciﬁcation
None 33 (60.0) 36 (65.5) 0.8
Moderate 10 (18.2) 8 (14.5) 0.8
Severe 12 (21.8) 11 (20.0) 0.8
Pre-dilation 55 (100.0) 55 (100.0) 1
Length of stented segment, mm 114  61 116  72 0.5
Concomitant BTK PTA 33 (60.0) 30 (54.5) 0.8
Technical successy 55 (100.0) 55 (100.0) 1
Procedural successz 53 (100.0) 51 (100.0) 1
Values are mean  SD or % (n). *Values are expressed as median (quartile range) and
compared with Mann-Whitney U test. yAchievement of >30% residual stenosis by visual
estimate. zAchievement of technical success without procedural complications.
BTK ¼ below-the-knee lesion; DS ¼ diameter stenosis; MLD ¼ minimal lumen diameter;
RVD ¼ reference vessel diameter; SFA ¼ superﬁcial femoral artery; other abbreviations as in
Table 1.
Table 3. 12-Month Target Lesion Evaluation
PEB þ BMS PTA þ BMS P Value
Lesions, n 55 55
Lesions evaluated, n* 53 55 0.9
Angiographic assessment 37 (69.8) 42 (76.4) 0.5
Duplex assessment 16 (30.2) 13 (23.6) 0.5
Restenosis 9 (17.0) 26 (47.3) 0.008
Lesions diagnosed by
angiography, n
8 (88.9) 22 (84.6) 0.5y
Lesions diagnosed by
DUS, n, PSVR 2.5
1 (11.1) 4(16.4)
RVD, mm 5.11  0.6 5.05  0.5 0.5
MLD, mm 3.59  1.42 2.12  1.47 <0.001
DS, %z 20.7 (17.7/27.0) 41.2 (34.8/82.3) <0.001
Late lumen loss, mmz 0.86 (0.80/0.94) 1.68 (1.60/4.2) <0.001
Values are n, % (n), or mean  SD. *Two patients died in the PEB þ BMS group before lesion
evaluation. yThe p value refers to a chi-squared test comparing the percentages of restenosis
diagnosed by angiography versus duplex in the 2 study groups. zValues are expressed as
median (quartile range) and compared with Mann-Whitney U test.
DUS ¼ duplex ultrasonography; PSVR ¼ peak systolic velocity ratio; other abbreviations as in
Tables 1 and 2.
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1298(collaterals, bone landmarks) and a second image showing
the inﬂated balloon(s). These images were compared with
follow-up angiograms.
Binary restenosis was deﬁned as a >50% diameter stenosis
(by angiography) or a peak systolic velocity ratio 2.5 (by
DUS) at follow-up. The in-stent restenosis (ISR) lesions
were classiﬁed by visual estimate on angiography: class I,
focal (50 mm in length) ISR group, included lesions
positioned at the stent body, the stent edge, or a combina-
tion of these sites; class II, diffuse (>50 mm in length)
ISR group, includes not only stent body lesions, but also
stent edge lesions; and class III is the totally occluded ISR
group (18). Angiograms and DUS scans were assessed in
a blinded fashion by independent operators and reviewed
by 2 readers without knowledge of clinical status and
randomization group.
The primary endpoint of the study was the comparison of
12-month binary restenosis rate, by either angiography or
DUS. The key secondary endpoint was the incidence of
TLR. TLR was only performed if clinically indicated
(reoccurrence of symptoms, either claudication or CLI), and
when a target lesion diameter stenosis of 50% was present.
Major amputation at 12 months, deﬁned as unplanned
amputation of the target limb where prosthesis was required
for standing or walking, was another secondary endpoint.
Post hoc exploratory comparisons were performed bet-
ween long (100 mm) versus shorter lesions and true lumen
versus subintimal recanalization. Finally, as a conﬁrmatoryanalysis, late lumen loss (LLL), deﬁned as the difference in
minimum lumen diameter of the target lesion between the
time points immediately following intervention and the
12-month follow-up angiography or at the time of a clini-
cally driven TLR was calculated by quantitative angiography
Figure 2. 12-Month Freedom From TLR
Kaplan-Meier curve comparing freedom from TLR between the 2 study groups
showing a near-signiﬁcant 1-year freedom from TLR advantage in the PEB
group. Abbreviations as in Figure 1.
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1299and compared between the PTA þ BMS and PEB þ BMS
groups.
Statistical analysis. The study sample size was powered to
demonstrate an absolute 25% reduction in binary restenosis
provided by PEB þ BMS as compared to PTA þ BMS. At
the time of study inception, data from the most pertinent
related studies were considered, showing a 1-year restenosis
rate of about 20% in patients treated with PEB (12) and
of 30% to 40% in those treated with stenting (19,20).
However, as our institutional activity is focused on diabetic
patients presenting with CLI (21), we expected to enroll
a higher-risk population, and a 12-month restenosis rate of
45% in the PTA þ BMS group was projected. Considering
a dropout rate of 5%, a sample size of 110 lesions was
deemed necessary to reach a statistical power of 80% (1 – ß
0.80; a ¼ 0.05).
Continuous data are expressed as mean values  SD.
Categorical variables were compared with the use of the
chi-square test or Fisher exact test. Student t tests for
independent samples were used to compare groups on
continuous variables.
Kaplan-Meier curves (log-rank [Mantel-Cox] test) were
used to compare freedom from TLR between the 2 study
groups. Statistical analyses were performed with SPSS
(version 17.0 for Windows, SPSS Inc., Chicago, Illinois).Results
Patients and lesions. Between November 2010 and
November 2011, 104 patients (110 lesions in 110 limbs)
were enrolled (Fig. 1). Clinical characteristics are summa-
rized in Table 1. The majority of patients was diabetic and
was referred for CLI. Baseline lesion and procedural char-
acteristics are presented in Table 2. Mean lesion length was
slightly less than 100 mm in both groups. Over 50% of the
lesions were total occlusions. Concomitant below-the-knee
revascularization was performed in 57% of cases, as clinically
needed. No signiﬁcant difference was observed between the
2 study groups in the incidence and outcome of these
revascularizations. Technical and procedural success was
achieved in all lesions.
Follow-up and clinical outcome. No major adverse events
occurred in-hospital. Two patients in the PEB þ BMS
group died before the 12-month assessment (1 due to heart
failure, the other due to sepsis). One patient in the PTA þ
BMS group died 2 weeks after target lesion follow-up eval-
uation due to sudden cardiac death (Fig. 1). No major
amputation occurred. Twelve-month evaluation is summa-
rized in Table 3. A total of 79 lesions (73%) were reviewed by
repeat angiography, whereas 29 lesions (27%) were evaluated
by ultrasonography (7 and 5 due to consent withdrawal for
control angiography, 9 and 8 due to severe renal impairment
in the PEB þ BMS and PTA þ BMS groups, respectively).The primary endpoint, binary restenosis, occurred in 9
(17%) versus 26 (47.3%) of lesions in PEB þ BMS and
PTA þ BMS groups, respectively (p ¼ 0.008). Kaplan-
Meier analysis showed a near-signiﬁcant 1-year freedom
from TLR advantage in the PEB group (Fig. 2).
Long lesions (100 mm) showed a reduced restenosis
rate in the PEB þ BMS versus PTA þ BMS groups (21%
vs. 62%, p ¼ 0.01) (Fig. 3). Restenosis rate was signiﬁcantly
lower in the PEB þ BMS than in the PTA þ BMS group,
irrespective of the recanalization approach (true lumen vs.
subintimal) (Fig. 4). LLL was signiﬁcantly lower in the
PEB þ BMS group compared with the PTA þ BMS group
(Table 3).
Three stent fractures (2 in the PEB group) were detected
at angiographic follow-up. At 12 months, 45 patients in the
PTA þ DEB group versus 30 in the PTA þ BMS group
improved at least 2 Rutherford classes (81.8% vs. 54.5%,
p ¼ 0.02).Discussion
The results of this randomized study indicate that a strategy
of PEB þ BMS is superior to conventional PTA þ BMS in
patients with complex, de novo femoropopliteal lesions,
signiﬁcantly reducing the primary endpoint of binary reste-
nosis of more than 2. This impressive result was even more
evident in very long lesions and was obtained irrespective of
the adopted technique (true lumen vs. subintimal). This
reduction in restenosis translated into a reduction in clini-
cally driven TLR of borderline signiﬁcance (Fig. 5).
Figure 3. Restenosis and Lesion Length
Restenosis rate in lesions 100 mm versus <100 mm: Long lesions (100
mm) showed a reduced restenosis rate in the PEB þ BMS versus PTA þ BMS
groups. LL ¼ lesion length; other abbreviations as in Figure 1.
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1300In femoropopliteal lesions, conventional PTA plus
nitinol stent strategy obtained encouraging results when
compared with standard PTA, but it still carries a relevant
risk of restenosis (2,20), especially in long and complex
lesions (19). Our trial showed an unfavorable outcome inFigure 4. Restenosis and Revascularization Technique
Restenosis rate in true lumen versus subintimal revascularization: Restenosis
rate was signiﬁcantly lower in the PEB þ BMS than in the PTA þ BMS group,
irrespective of the recanalization approach (true lumen vs. subintimal).
Abbreviations as in Figure 1.the PTA þ BMS group when compared with PEB.
Previous preliminary observational data reported for the
Maris stent (Medtronic, Minneapolis, Minnesota) showed
an increased risk of restenosis/reocclusion (22), and this
could partly explain our results. In the RESILIENT
(Randomized Study Comparing the Edwards Self-
Expanding Lifestent versus Angioplasty Alone in Lesions
Involving the SFA and/or Proximal Popliteal Artery) trial,
Laird et al. (2) randomized 206 patients with obstructive
lesions of the superﬁcial femoral and proximal popliteal
arteries and intermittent claudication to stenting versus
standard PTA. The stent group (n ¼ 134) showed
a freedom from TLR rate of 87.3% at 12 months. If
compared with these data, we observed a clearly higher
TLR rate in the PTA þ BMS group. However, the
RESILIENT stent population was younger as compared
with our sample (68 vs. 76 years), with a lower percentage of
diabetes (40% vs. 70%), had better ankle-brachial index
(0.71 vs. 0.31) and clinical status (0% vs. 68% of patients in
Rutherford class 4), lesion length was 70 mm versus 96
mm, and total occlusions were 17% versus 69.1%.
In the setting of femoropopliteal lesions, even sirolimus-
and everolimus-eluting stents have failed to demonstrate
additional beneﬁt (7–9,23,24), whereas paclitaxel (an irre-
versible inhibitor of microtubules polymerization) (17) DES
perform signiﬁcantly better than BMS do (10). DES,
however, though providing a mechanical scaffold, are
potentially limited by the nonhomogeneous wall contact of
the drug and by the long-term irritative effect of metal and
polymer (25).
The use of DEB may be an effective alternative to DES,
as any stentless technology for the improvement of long-
term patency might be preferable to the long-term persis-
tence of a foreign body. Potential drawbacks of a DEB-alone
strategy, however, are the elastic recoil phenomenon, and
the occurrence of ﬂow-limiting dissection, as very calciﬁc
stenosis or total occlusions are commonly found in the fem-
oropopliteal vessels. It is indeed likely that the rate of
bailout stenting for such complex lesions in real-world inter-
ventions is higher than the 10% to 20% reported in DEB
randomized trials (26) or registries (27).
Whereas DAPT is recommended for at least 1 month
after infrainguinal BMS implantation (28), there is still
no consensus about the duration of DAPT following
DEB þ PTA (ranging from 1 to 3 months or more in
different studies [12,13,27]), and particularly in the case of
PEB þ stent implantation. As per protocol design, we
administered a 3-month DAPT in patients treated with
PEB and stent implantation to limit the occurrence of stent
thrombosis, which could arise from incomplete stent strut
re-endothelization due to the antiproliferative effect of the
paclitaxel. Such duration appeared safe; of note, no stent
thrombosis was observed in our study population during the
follow-up period.
Figure 5. Comparison in a Single Patient With Bilateral, Specular SFA Lesions of the Effects of PEB Versus Conventional Angioplasty
This 73-year-old man was treated on the left limb (A to C) prior to study enrollment with conventional angioplasty plus stent, whereas the right superﬁcial femoral
artery (SFA) received PEB prior to stenting as part of the study (D to F). Twelve-month angiographic follow-up (at different time points) is reported, showing diffuse
neointimal regrowth with focal areas of signiﬁcant (>50%) restenosis on the left side versus maintained patency on the right side. Abbreviations as in Figure 1.
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1301To our knowledge, the DEBATE SFA study is the ﬁrst
randomized trial to investigate the efﬁcacy and safety of
PEB angioplasty prior to systematic nitinol self-expanding
stent implantation versus conventional PTA followed
by stenting in patients at high risk of restenosis. In
the recently published PACIFIER (Paclitaxel-Coated
Balloons in Femoral Indication to Defeat Restenosis) trial
(which tested the same DEB platform) (14), procedural
protocol limited stent use only for provisional or bailout
situations. Stents were actually employed in only about
20% of patients enrolled in both arms. Target lesions
binary restenosis rate was 8.6% in DEB plus provisional/
bailout stenting, which appears lower than the 17% rate
observed in the DEB plus systematic stenting arm of the
present study. However, we enrolled more diabetics (73%
vs. 35.5%), more patients in Rutherford class 4 (74% vs.
4%), dialysis patients were not excluded, mean lesion
length was longer (approximately 95 mm vs. 70 mm), and
total occlusions were more frequently present (62% vs.
31%). It is thus likely that the baseline characteristics of the
enrolled population might explain this discrepancy.
Our study also provides some insights regarding the
issue of DEB safety. The achieved reduction in binary
restenosis and TLR was due to a sizable reduction in neo-
intimal regrowth, which was nonetheless uniformly present,
with a positive LLL of around 1.3 mm. No cases of negative
LLL (associated in the coronary experience with stent mal-
apposition and ultimately thrombotic event [29]) or arterial
aneurysm were seen. It should be noted that a negative LLL
has recently been observed in some patients treated withPEB in the PACIFIER trial, especially in those with the
most severe baseline stenoses (14). This discordant ﬁnding,
besides the obvious effect of stenting, may be potentially
explained by the different procedural DEB deployment
technique, which involved, in our study, aggressive lesion
preparation with an uncoated balloon prior to DEB in all
patients, whereas pre-dilation was adopted in <10% of
patients of the PACIFIER trial. Nonuniform drug distri-
bution by the very compliant DEB (17) when inﬂated in
complex stenosis could potentially explain this effect.
Study limitations. First, the study reﬂects a single-center
experience and involves a relatively small sample, which,
although sufﬁcient to detect differences in the primary
endpoint, was not powered to test differences in hard clinical
endpoints. Second, evaluation of binary restenosis was per-
formed in most cases by angiography; however, the use of
ultrasonography in a small percentage of patients could
represent a potential bias. Third, we chose to perform sys-
tematic stenting in both groups. Our sample, however, was
procedurally complex and this strategy reﬂects our current
practice in high-risk patients. We concede, however, that
this is a controversial point and that our study does not
provide an answer. Finally, due to the ﬁnancial constraints
of running an independent trial, an external data adjudica-
tion committee or core lab was lacking.
Conclusions
The DEBATE-SFA trial demonstrates that pre-dilation
with PEB angioplasty prior to nitinol self-expanding stent
Liistro et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 1 2 , 2 0 1 3
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1302implantation, compared with conventional PTA followed by
stenting, reduces restenosis and TLR at 12-month follow-
up. Restenosis reduction is maintained irrespective of lesion
length and recanalization technique. Further studies may
conﬁrm whether a systematic or provisional stenting strategy
is preferred when using DEB, or they may investigate and
compare PEB þ BMS strategy with newer DES technology.
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